New Fusions Added to Lung Cancer Testing Panel
New Fusions Added to Lung Cancer Testing Panel

Sponsor: Paradigm Diagnostics


Paradigm Cancer Diagnostic (PCDx) lung cancer testing panels were recently expanded to also include 17 fusions, as well as EGFR and MET skipping events. The fusions include: ALK, AXL, BRAF, CCND1, FGFR1, FGFR2, FGFR3, MET, NGR1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS1, and THADA. The fusion panel may also be ordered as an add-on for any PCDx patients for standard five-day turnaround. Paradigm uses anchored PCR technology on RNA to detect known and novel fusions with high sensitivity using a tissue requirement of 4% or greater tumor content in a single core needle biopsy or fine needle aspirate. PCDx is a clinical-grade comprehensive sequencing test that covers DNA, RNA, fusions, and immunohistochemistry and interrogates the most actionable targets with a 5,000x average depth of coverage and delivers a report in five business days using the latest evidence with associations including associations to up to 87 different FDA approved therapies and 19 combinations.

This site uses Akismet to reduce spam. Learn how your comment data is processed.